March 24, 2017 / 7:09 AM / 6 months ago

BRIEF-Sun Pharma says filing of tildrakizumab with European Medicines Agency by Almirall

March 24 (Reuters) - Sun Pharmaceutical Industries Ltd

* Says validation of regulatory filing of tildrakizumab with the european medicines agency (EMA) by Almirall.

* Tildrakizumab is an investigational IL-23P19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis.

* Filing includes efficacy, safety data from pivotal phase III clinical trials that included over 1,800 patients Source text - (bit.ly/2obIqtz) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below